What precautions should be taken when using the Lao Lucius version of Mobotinib?

Mobotinib, this targeted drug for EGFR-positive non-small cell lung cancer (NSCLC), effectively inhibits the growth and reproduction of cancer cells by blocking the abnormal EGFR protein produced by exon 20 insertion mutations. In the Laotian market, the generic version of Mobotinib produced by Lucius Pharmaceuticals is favored by patients because of its relatively affordable price. However, when using mobotinib as a prescription medicine, there are a number of important things that patients need to know and follow to ensure that the treatment is both safe and effective.

Before using the Laos version of Mobotinib, patients must first confirm whether they are suitable for this drug. It is mainly suitable for patients with locally advanced or metastatic NSCLC caused by EGFR exon 20 insertion mutations, and whose disease worsens during or after treatment with platinum-containing chemotherapy drugs. Therefore, genetic testing is an essential step to confirm whether a patient has this specific genetic mutation.

During the medication process, patients should strictly follow the doctor's instructions to take mobotinib. Usually, the recommended dose is 160 mg once daily, preferably at the same time every day to maintain stable blood concentration. Patients can choose to take it on an empty stomach or with a meal, but consistency is recommended. If you miss a dose and the missed dose lasts more than 6 hours, you do not need to take it again. You only need to continue taking the regular dose at the next dose time.

In addition, patients should pay close attention to their body's reaction while taking mobotinib. Mobotinib may cause some adverse reactions, such as diarrhea, rash, nausea, vomiting, etc. If serious adverse reactions occur, patients should stop taking the medicine immediately and seek medical help promptly. At the same time, patients also need to regularly monitor heart function and lung conditions, as well as liver function tests, so that possible problems can be discovered and dealt with in a timely manner.

In summary, the Laos Lucius version of mobotinib provides a new treatment option for EGFR-positive NSCLC patients. However, when using it, patients must strictly follow the doctor's instructions and pay attention to all aspects of medication and precautions to ensure the safety and effectiveness of the treatment.

References:

https://www.drugs.com/search.php?searchterm=Exkivity&sources%5B%5D=professional